Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Goebell

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Der Urologe. Ausg. A|May 2, 2019
[Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine]C Wülfing, M Bögemann, P J Goebell, et al.
Der Urologe. Ausg. A|June 26, 2019
C Wülfing, M Bögemann, P J Goebell, et al.
Der Urologe. Ausg. A|October 11, 2019
[Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence]F König, A Strauß, M Johannsen, et al.
Der Urologe. Ausg. A|June 23, 2006
[Noninvasive and invasive bladder cancer: diagnostics and treatment]P J Goebell, F Vom Dorp, C Rödel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trialT Powles, S Tagawa, C Vulsteke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trialL Bergmann, L Albiges, M Ahrens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†A Kramar, S Negrier, R Sylvester, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Der Urologe. Ausg. A|May 2, 2019
[Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine]C Wülfing, M Bögemann, P J Goebell, et al.
Der Urologe. Ausg. A|June 26, 2019
C Wülfing, M Bögemann, P J Goebell, et al.
Der Urologe. Ausg. A|October 11, 2019
[Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence]F König, A Strauß, M Johannsen, et al.
Der Urologe. Ausg. A|June 23, 2006
[Noninvasive and invasive bladder cancer: diagnostics and treatment]P J Goebell, F Vom Dorp, C Rödel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trialT Powles, S Tagawa, C Vulsteke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trialL Bergmann, L Albiges, M Ahrens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†A Kramar, S Negrier, R Sylvester, et al.
Pageof 4